

Online Supplementary Table 3: Relevant medical history and current medical conditions**(Safety patients*)**

Preferred term, n (%)	Total (N = 936)	Unilaterally treated (n = 823)	Bilaterally treated (n = 113)
Any relevant medical history/current medical condition	902 (96.4)	792 (96.2)	110 (97.4)
Hypertension	579 (61.9)	509 (61.9)	70 (62.0)
Hypercholesterolemia	189 (20.2)	166 (20.2)	23 (20.4)
Diabetes mellitus	107 (11.4)	100 (12.2)	7 (6.2)
Menopause	103 (11.0)	87 (10.6)	16 (14.2)
nAMD	79 (8.4)	72 (8.8)	7 (6.2)
Cataract	76 (8.1)	62 (7.5)	14 (12.4)
Benign prostatic hyperplasia	65 (6.9)	55 (6.7)	10 (8.9)
Osteoporosis	65 (6.9)	57 (6.9)	8 (7.1)
Cataract nuclear	59 (6.3)	53 (6.4)	6 (5.3)
Hypothyroidism	58 (6.2)	50 (6.1)	8 (7.1)
Atrial fibrillation	41 (4.4)	32 (3.9)	9 (8.0)
Glaucoma	41 (4.4)	34 (4.1)	7 (6.2)

*Consisted of all enrolled patients who signed the informed consent, received at least one dose of study drug and had at least one post-baseline safety assessment.

Preferred terms $\geq 5\%$ incidence in any group are included.

nAMD, neovascular age-related macular degeneration; SOC, system organ class